标题:
Quantitative Monitoring and Mutation of ctDNA before and after Non-Small Cell Lung Cancer Radical Surgery
讲者:
陈湘琦
单位:
福建医科大学附属协和医院
播放:
726
论文摘要:
Objective:To study the quantitative expression of ctDNA in patients with non-small cell lung cancer before and after radical operation.To explore the relationship between the mutation of gene mutations in non small cell lung cancer tissues and the detection of mutant genes in ctDNA.
Methods:We randomly assigned 5 NSCLC patients from the Department of Thoracic Surgery of Fujian Medical University Union Hospital,all patients underwent radical surgery.Collection the venous blood samples from the 5 NSCLC patients at two time points(before the operation, 21-37 days after operation) for monitoring ctDNA levels,isolated plasma from veinal blood by using high velocity centrifugal,extracted plasma DNA utilize QIAamp Circulating Nucleic Acid kit,methods quantificationally measuring ctDNA level.The results were analyzed by Wilcoxon Rank Sum Test.Meanwhile,compared with the expression level of CEA which were simultaneous collection and detection with ctDNA.Tumor tissue,peripheral blood cells,ctDNA were sequenced used by Hiseq2000 sequencing platform (Illumina) ,and then screen out mutant gene. Mutation occur with tumor tissue as a positive control,preoperative blood cells as a negative control,the mutation of ctDNA gene,a total of 508 genes related to cancer,was analyzed.
Results:the medians of pre- and post-operative ctDNA levels in five patients with NSCLC were 0.612 (0.518-0.876) and 0.430 (0.372-0.612) ng/μL, respectively.there was significant difference between two groups (P<0.05),The preoperative CEA level was slightly higher than the postoperative level (P>0.05).LC tissue showed multiple consistent mutation with preoperative ctDNA in one case,Moreover,no isogenic mutation of same type was detected in postoperative ctDNA or peripheral blood cells.
Conclusion:mutation of LC ctDNA gene is consistent with the mutation type of LC tissue;the quantitative and qualitative analysis of ctDNA is a promising novel molecular biomarker in evaluating the tumor burden changes in NSCLC.